poisar

Stocks · News reference

B of A Securities Maintains Underperform on RxSight, Lowers Price Target to $5.5

Benzinga Newsdesk

B of A Securities analyst Craig Bijou maintains RxSight (NASDAQ:RXST) with a Underperform and lowers the price target from $6.5 to $5.5.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

RXST
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

    K2 Vision, a Pacific Northwest and Arizona-based vision correction practice, has completed 5,000 Light Adjustable Lens (LAL) procedures and been recognized by RxSight as the world's highest-volume LAL practice. The LAL is the first lens implant that can be adjusted after placement through noninvasive light treatments, allowing for customized vision correction based on patient needs.

    RXST